Confronto

Enfuvirtid vs. Pasireotid

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Ricerca (altro)

N. CAS

159519-65-0

396091-73-9

Peso molecolare

4491.88 g/mol

1047.21 g/mol

Emivita

nessun dato

Sequenza

nessun dato

Meccanismo d'azione

Enfuvirtid

Enfuvirtide binds the first heptad-repeat region (HR1) of the gp41 subunit of the HIV envelope protein. This prevents the conformational change required for fusion of the viral and cell membranes — the virus cannot enter the cell.

Pasireotid

Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.

Base di evidenze

Evidenza più alta

RCT sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	Enfuvirtid	Pasireotid
Germania	Su prescrizione	Su prescrizione
Stati Uniti	Su prescrizione	Su prescrizione

Voci complete

Frequently asked questions

What is the difference between Enfuvirtid and Pasireotid?: Enfuvirtid is classified as "Ricerca (altro)", while Pasireotid is classified as "Ricerca (altro)". Enfuvirtid: Enfuvirtide is a synthetic 36-amino-acid peptide and the first HIV-1 fusion inhibitor. It binds the HR1 region of the viral envelope protein gp41, blocking viral entry into the cell. Approved for treatment-experienced HIV patients. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Enfuvirtid or Pasireotid?: The highest available evidence level is "RCT sull'uomo" for Enfuvirtid and "RCT sull'uomo" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Enfuvirtid and Pasireotid in Germany and the United States?: Germania: Enfuvirtid — Su prescrizione, Pasireotid — Su prescrizione. Stati Uniti: Enfuvirtid — Su prescrizione, Pasireotid — Su prescrizione. These are factual summaries with source and review date on the individual pages.

Country

Enfuvirtid

Pasireotid

Germania

Su prescrizione

Stati Uniti

Su prescrizione

Frequently asked questions

What is the difference between Enfuvirtid and Pasireotid?

Enfuvirtid is classified as "Ricerca (altro)", while Pasireotid is classified as "Ricerca (altro)". Enfuvirtid: Enfuvirtide is a synthetic 36-amino-acid peptide and the first HIV-1 fusion inhibitor. It binds the HR1 region of the viral envelope protein gp41, blocking viral entry into the cell. Approved for treatment-experienced HIV patients. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Enfuvirtid or Pasireotid?

The highest available evidence level is "RCT sull'uomo" for Enfuvirtid and "RCT sull'uomo" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Enfuvirtid and Pasireotid in Germany and the United States?

Germania: Enfuvirtid — Su prescrizione, Pasireotid — Su prescrizione. Stati Uniti: Enfuvirtid — Su prescrizione, Pasireotid — Su prescrizione. These are factual summaries with source and review date on the individual pages.